CHMA Chiasma Inc.

-0.11  -2%
Previous Close 4.99
Open 5
Price To Book 4
Market Cap 203,921,668
Shares 41,787,227
Volume 934,621
Short Ratio
Av. Daily Volume 977,838

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

NDA filing due 4Q 2019.
Mycapssa - OPTIMAL
CRL April 15 2016
Phase 3 data due 2H 2020.
Mycapssa - MPOWERED
Maintenance treatment of adult acromegaly

Latest News

  1. Chiasma (CHMA) Upgraded to Buy: Here's Why
  2. Edited Transcript of CHMA earnings conference call or presentation 8-Aug-19 9:00pm GMT
  3. Chiasma Inc (CHMA) Q2 2019 Earnings Call Transcript
  4. Chiasma Reports Second Quarter 2019 Results
  5. Chiasma to Report Second Quarter Financial Results on August 8, 2019
  6. Steven Cohen Charges Into Chiasma
  7. Chiasma Announces Pricing of Underwritten Public Offering of $55.0 Million of Common Stock
  8. Chiasma Announces Proposed Offering of Common Stock
  9. Here Is What's Driving The Rally In Chiasma
  10. Chiasma Announces Positive Phase 3 Top-Line Results from CHIASMA OPTIMAL Clinical Trial of Mycapssa® for the Maintenance Treatment of Adults with Acromegaly
  11. One Thing To Remember About The Chiasma, Inc. (NASDAQ:CHMA) Share Price
  12. 18 Stocks Joining The Russell Indices
  13. The Daily Biotech Pulse: Chiasma To Join R3K Index, EU Rejects Amgen's Osteoporosis Drug Application, Karuna IPO
  14. Chiasma Set to Join Russell 3000® Index
  15. Chiasma Provides Update on Ongoing Mycapssa® Phase 3 Clinical Trials
  16. The Daily Biotech Pulse: Takeda Pulls Plug On Amyloidosis Drug Trial, Chiasma Preps For Drug Launch With New CEO Appointment, Orchard Prices Offering
  17. Chiasma Strengthens Leadership Team Ahead of Anticipated Commercial Availability of Mycapssa®
  18. Chiasma (CHMA) Catches Eye: Stock Jumps 9.7%
  19. Will Chiasma to Surge Higher?
  20. Edited Transcript of CHMA earnings conference call or presentation 9-May-19 9:00pm GMT